Our delivery technologies enable many pharmaceutical products to improve patient health by enhancing the efficacy, safety, and ease of use of the drug, as well as the delivery of a therapeutic to its target site, minimizing off-target accumulation and facilitating patient compliance.
Our proprietary platform, a unique and novel technology, through this technology that BDT creates innovation in topical dermatology products and addresses unmet patient needs.
The skin is the largest organ of the body, skin diseases are the fourth most common cause of all human disease, affecting almost one-third of the world’s population, yet their burden is often underestimated, despite their visibility.
Almost half (42%) of patients with skin disease experience sleep disturbances, The main symptoms that impacted the sleep of patients with skin disease were itching (60%) and burning sensations or tingling (17%).
Skin diseases can have a significant impact on patients’ quality of life, leading to psychosocial costs.
The economic burden of skin diseases is not limited to individual countries but has a global impact. Skin diseases affect populations in both high-income and low-income countries, and their economic consequences are felt worldwide.
Cofounder & General Manager
Eryc is the Cofounder & General Manager at Bio-dtek. Eryc has experience in the production of over sixty different generic drugs and super-generic drugs. He possess rich experience in various dosage forms and processes, which allows for more efficient reduction of development timelines and cost.
Eryc is the inventor of more than 20 issued patents/patent applications and author of scientific papers, and has won a silver medal of National Invention Award in 2011.
With previous experiences,those formula platforms Eryc expertise :
Vice President, Streategy and Marketing
Dr. Mei-Ling Cheng brings over 15 years of experience in BD, commercialization, manufacturing, and R&D roles, She joins Bio-dtek as Vice President of strategy and marketing.
Dr. Cheng is responsible for partnership engagement, sales and marketing, and business development. She will lead external communications for Bio-dtek’s full product pipeline and delivering enterprise communications for the global business.
Vice President, Operation Managemnt
Jack is Vice President of operations and management at Bio-dtek, Jack has over 25 years of experience in strategic planning, BD, finance, IT management and operating roles. Here, he is responsible for growth-oriented activities and build the commercial operations infrastructure to support the organization’s high growth.
Consultant
Lynn Tuan has great regulatory affairs professional experience in drug development. Her regulatory expertise spans both US and ex-US submissions and strategies (IND/CTA/sBLA), FDA meetings, communications with global regulatory agencies. She serves as a consultant to regulatory strategy, IND submission and clinical management.
Bio-dtek Pharmaceutical Co., Ltd.
11F.-5, No 136, Sec. 3, Zhongxiao E. Rd., Daan District, Taipei City, Taiwan
© 2026 晟誼生醫 BIO-DTEK. All Rights Reserved.
